WO2009088401A3 - Immunostimulatory combinations of tlr3 ligands with tlr2 and/or tlr9 agonists and methods of use - Google Patents

Immunostimulatory combinations of tlr3 ligands with tlr2 and/or tlr9 agonists and methods of use Download PDF

Info

Publication number
WO2009088401A3
WO2009088401A3 PCT/US2008/011236 US2008011236W WO2009088401A3 WO 2009088401 A3 WO2009088401 A3 WO 2009088401A3 US 2008011236 W US2008011236 W US 2008011236W WO 2009088401 A3 WO2009088401 A3 WO 2009088401A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tlr2
immunostimulatory
immunostimulatory combinations
tlr9 agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/011236
Other languages
French (fr)
Other versions
WO2009088401A2 (en
Inventor
Jay A. Berzofsky
Qing Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to EP08870520.7A priority Critical patent/EP2200639B1/en
Priority to US12/679,881 priority patent/US9421254B2/en
Publication of WO2009088401A2 publication Critical patent/WO2009088401A2/en
Publication of WO2009088401A3 publication Critical patent/WO2009088401A3/en
Anticipated expiration legal-status Critical
Priority to US15/244,882 priority patent/US20170165359A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides immunostimulatory combinations of TLR ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions.
PCT/US2008/011236 2007-09-24 2008-09-24 Immunostimulatory combinations of tlr ligands and methods of use Ceased WO2009088401A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08870520.7A EP2200639B1 (en) 2007-09-24 2008-09-24 Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
US12/679,881 US9421254B2 (en) 2007-09-24 2008-09-24 Immunostimulatory combinations of TLR ligands and methods of use
US15/244,882 US20170165359A1 (en) 2007-09-24 2016-08-23 Immunostimulatory combinations of tlr ligands and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99521207P 2007-09-24 2007-09-24
US60/995,212 2007-09-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/679,881 A-371-Of-International US9421254B2 (en) 2007-09-24 2008-09-24 Immunostimulatory combinations of TLR ligands and methods of use
US15/244,882 Continuation US20170165359A1 (en) 2007-09-24 2016-08-23 Immunostimulatory combinations of tlr ligands and methods of use

Publications (2)

Publication Number Publication Date
WO2009088401A2 WO2009088401A2 (en) 2009-07-16
WO2009088401A3 true WO2009088401A3 (en) 2009-10-15

Family

ID=40853652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/011236 Ceased WO2009088401A2 (en) 2007-09-24 2008-09-24 Immunostimulatory combinations of tlr ligands and methods of use

Country Status (3)

Country Link
US (2) US9421254B2 (en)
EP (1) EP2200639B1 (en)
WO (1) WO2009088401A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103800906B (en) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 For stimulating mammal to the composition of the congenital immunity resistance of pathogen
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
FR2954703B1 (en) 2009-12-28 2013-12-13 Chu Nantes TLR 4 AND 9 RECEPTOR AGONISTS TO PREVENT SEPTIC COMPLICATIONS OF POSTTRAUMATIC IMMUNODEPRESSION IN HOSPITAL PATIENTS FOR SEVERE INJURIES
EP2536425B1 (en) * 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (en) 2010-03-30 2013-02-20 西奈山医学院 Influenza virus vaccines and uses thereof
US9890202B2 (en) * 2010-07-19 2018-02-13 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (TLR) for treatment of TLR-mediated diseases
WO2012014945A1 (en) * 2010-07-28 2012-02-02 国立大学法人北海道大学 Novel nucleic acid having adjuvant activity and use thereof
WO2012054425A2 (en) * 2010-10-18 2012-04-26 University Of Iowa Research Foundation Biodegradable particulate formulations
WO2012065755A1 (en) 2010-11-19 2012-05-24 Bavarian Nordic A/S Production of ifn-lambda by b cells
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US20130297023A1 (en) * 2012-05-07 2013-11-07 Hee-Jeong Im Sampen Methods and Devices For Treating Intervertebral Disc Disease
EP2732825B1 (en) * 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
TR201908550T4 (en) 2014-06-04 2019-07-22 Exicure Inc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications.
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof
WO2017067593A1 (en) * 2015-10-21 2017-04-27 Biontech Ag Methods and means for inducing an immune response
EP4483903A3 (en) 2016-04-01 2025-04-02 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
US12508279B2 (en) 2016-04-01 2025-12-30 Colorado State University Research Foundation Compositions and methods for enhancing innate immunity in a subject for treatment of infections and cancer and other acute and chronic conditions of the eye
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
MX2018015755A (en) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Influenza virus hemagglutinin proteins and uses thereof.
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11826422B2 (en) 2016-11-09 2023-11-28 Board Of Regents, The University Of Texas System Methods and compositions for adaptive immune modulation
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
CN106834454B (en) * 2017-01-17 2020-12-25 北京大学第一医院 Kit and method for detecting whether male can be naturally cleared after being infected with HBV
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
MX2019015076A (en) * 2017-06-15 2020-08-03 Infectious Disease Res Inst Nanostructured lipid carriers and stable emulsions and uses thereof.
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020023872A1 (en) * 2018-07-27 2020-01-30 Children's Medical Center Corporation Use of toll-like receptor 2 (tlr-2) agonist for modulating human immune response
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
US12419965B2 (en) 2018-10-01 2025-09-23 BioNTech SE RNA particles comprising polysarcosine
CA3128386A1 (en) 2019-02-04 2020-08-13 Codiak Biosciences, Inc. Membrane protein scaffolds for exosome engineering
BR112021018694A2 (en) 2019-03-21 2021-11-30 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
WO2021034729A1 (en) * 2019-08-16 2021-02-25 The Regents Of The University Of California N-aryl sulfonamide derivatives as vaccine adjuvant
MX2022003570A (en) 2019-09-25 2022-07-11 Codiak Biosciences Inc Extracellular vesicle compositions.
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (en) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド Extracellular vesicles for therapy
US20210317454A1 (en) * 2020-04-10 2021-10-14 Idera Pharmaceuticals, Inc. Use of a tlr9 agonist in methods for treating covid-19
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
JP2023532717A (en) 2020-07-02 2023-07-31 ヴィーブ ヘルスケア カンパニー Methods of achieving HIV viral remission with long-acting antiretroviral agents
AU2021338560A1 (en) * 2020-09-03 2023-04-06 ISR Immune System Regulation Holding AB (publ) Vaccine comprising an antigen and a TLR2 agonist
US20240082389A1 (en) 2020-09-23 2024-03-14 Lonza Sales Ag Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014335A1 (en) * 2001-08-08 2003-02-20 Bioclones (Proprietary) Limited Process for the maturation of dentritic cells and a vaccine
WO2005012509A2 (en) * 2003-08-04 2005-02-10 Imba-Institut Für Molekulare Biotechnologie Gmbh Method for immunotherapy of tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014335A1 (en) * 2001-08-08 2003-02-20 Bioclones (Proprietary) Limited Process for the maturation of dentritic cells and a vaccine
WO2005012509A2 (en) * 2003-08-04 2005-02-10 Imba-Institut Für Molekulare Biotechnologie Gmbh Method for immunotherapy of tumors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAGCHI ARANYA ET AL: "MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists", JOURNAL OF IMMUNOLOGY, vol. 178, no. 2, January 2007 (2007-01-01), pages 1164 - 1171, XP002541025, ISSN: 0022-1767 *
BOHNENKAMP ET AL: "Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type I responses", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 247, no. 2, 24 October 2007 (2007-10-24), pages 72 - 84, XP022323567, ISSN: 0008-8749 *
NAPOLITANI GIORGIO ET AL: "Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells", NATURE IMMUNOLOGY, vol. 6, no. 8, August 2005 (2005-08-01), pages 769 - 776, XP002541024, ISSN: 1529-2908 *
TRINCHIERI GIORGIO ET AL: "Cooperation of Toll-like receptor signals in innate immune defence", NATURE REVIEWS IMMUNOLOGY, vol. 7, no. 3, March 2007 (2007-03-01), pages 179 - 190, XP002541028, ISSN: 1474-1733 *
VANHOUTTE ET AL: "Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 116, no. 1, 17 December 2007 (2007-12-17), pages 86 - 94, XP022441918, ISSN: 0165-2478 *
VERDIJK R M ET AL: "Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 163, no. 1, 1 July 1999 (1999-07-01), pages 57 - 61, XP002214496, ISSN: 0022-1767 *
WARGER TOBIAS ET AL: "Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo", BLOOD, vol. 108, no. 2, July 2006 (2006-07-01), pages 544 - 550, XP002541026, ISSN: 0006-4971 *
WHITMORE M M ET AL: "SYNERGISTIC ACTIVATION OF INNATE IMMUNITY BY DOUBLE-STRANDED RNA AND CPG DNA PROMOTES ENHANCED ANTITUMOR ACTIVITY", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 64, no. 16, 15 August 2004 (2004-08-15), pages 5850 - 5860, XP009051341, ISSN: 0008-5472 *
ZHU QING ET AL: "Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 42, October 2008 (2008-10-01), pages 16260 - 16265, XP002541027, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2009088401A2 (en) 2009-07-16
US9421254B2 (en) 2016-08-23
US20170165359A1 (en) 2017-06-15
US20100297165A1 (en) 2010-11-25
EP2200639A2 (en) 2010-06-30
EP2200639B1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
WO2009088401A3 (en) Immunostimulatory combinations of tlr3 ligands with tlr2 and/or tlr9 agonists and methods of use
WO2008039390A3 (en) Compositions and methods for chitosan enhanced immune response
WO2008118587A3 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
EP4302782A3 (en) Napi2b-targeted antibody-drug conjugates and methods of use thereof
MX337838B (en) Bifidobacteria crispr sequences.
WO2011139348A3 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
MX2009001412A (en) Protein matrix vaccines and methods of making and administering such vaccines.
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
MY169837A (en) Immunogenic compositions of staphylococcus aureus antigens
WO2007109812A3 (en) Immunopotentiating compounds
MY161495A (en) Virus like particle compositions and methods of use
EP4303236A3 (en) Cytotoxicity-inducing therapeutic agent
HK1208216A1 (en) Drug-conjugates, conjugation methods, and uses thereof
WO2009026574A3 (en) Immunogenic compositions and uses thereof
WO2007079448A3 (en) Three component carbohydrate vaccine
MX2015002482A (en) Immunogenic composition.
WO2012073047A3 (en) Compositions and methods
WO2012013020A8 (en) Anti-fatigue composition, formulation and use thereof
CA2899089C (en) Factor ix polypeptide formulations
WO2016191179A8 (en) In vitro models of regenerative muscle cell therapy and uses thereof
CA3036643C (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
PH12013500392A1 (en) Theobromine in combination with an expectorant or a mucolytic for use in therapy
MX344189B (en) Formulations of mazindol.
PH12015500049B1 (en) Novel protein material
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08870520

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008870520

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12679881

Country of ref document: US